A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Antitumor Activity of JMT106 Injection in Patients With Advanced Solid Tumors
Latest Information Update: 06 Jan 2026
At a glance
- Drugs JMT 106 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Shanghai JMT-BIO Technology
Most Recent Events
- 06 Jan 2026 New trial record